(Q40291797)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28295019%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

title

M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28295019%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28295019%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Mats Bemark

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28295019%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

Karim El Bakkouri

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28295019%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

12

X Saelens

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28295019%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

11

W Fiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28295019%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

author name string

D G Eliasson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28295019%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

K Schön

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28295019%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

U A Wenzel

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28295019%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

V Bernasconi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28295019%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

A Kolpe

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28295019%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

T Ysenbaert

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28295019%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

L Deng

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28295019%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

N Lycke

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28295019%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

publication date

1 March 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28295019%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28295019%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28295019%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28295019%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

page(s)

273-289

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28295019%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/mi.2017.14

5 April 2020

exact match

0 references

cites work

Universal influenza vaccines, science fiction or soon reality?

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Prospects for universal influenza virus vaccine

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Influenza vaccines: challenges and solutions

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Current and next generation influenza vaccines: Formulation and production strategies

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Development of universal influenza vaccines based on influenza virus M and NP genes.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Virus-specific T cells as correlate of (cross-)protective immunity against influenza.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Cellular immune correlates of protection against symptomatic pandemic influenza.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

An Intranasal Virus-Like Particle Vaccine Broadly Protects Mice from Multiple Subtypes of Influenza A Virus.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Mucosal immunity and nasal influenza vaccination

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Localized mucosal response to intranasal live attenuated influenza vaccine in adults

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Universal influenza A vaccine: optimization of M2-based constructs.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

A novel subnucleocapsid nanoplatform for mucosal vaccination against influenza virus that targets the ectodomain of matrix protein 2.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Mucosal immunization with a candidate universal influenza vaccine reduces virus transmission in a mouse model.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

VACCINES. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Cutting edge: Tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Recombinant IgA is sufficient to prevent influenza virus transmission in guinea pigs

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

A common solution to group 2 influenza virus neutralization

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Multiple redundant effector mechanisms of CD8+ T cells protect against influenza infection

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

A universal influenza A vaccine based on the extracellular domain of the M2 protein

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

M2e-based universal influenza A vaccine

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Soluble recombinant influenza vaccines

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

M2e-Based Universal Influenza A Vaccines

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Genetic control of immune responses to influenza A matrix 2 protein (M2)

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

A human multi-epitope recombinant vaccinia virus as a universal T cell vaccine candidate against influenza virus

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Antibodies and CD4(+) T-cells mediate cross-protection against H5N1 influenza virus infection in mice after vaccination with a low pathogenic H5N2 strain

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Memory CD4+ T cells protect against influenza through multiple synergizing mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Multipronged CD4(+) T-cell effector and memory responses cooperate to provide potent immunity against respiratory virus

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

A unique role of the cholera toxin A1-DD adjuvant for long-term plasma and memory B cell development

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Defining in vivo dendritic cell functions using CD11c-DTR transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Intravascular staining for discrimination of vascular and tissue leukocytes.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

T cell mediated immunity to influenza: mechanisms of viral control

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

A GFP expressing influenza A virus to report in vivo tropism and protection by a matrix protein 2 ectodomain-specific monoclonal antibody

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the Head

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

T cells primed by influenza virion internal components can cooperate in the antibody response to haemagglutinin

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Hallmarks of CD4 T cell immunity against influenza

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

An early CD4+ T cell-dependent immunoglobulin A response to influenza infection in the absence of key cognate T-B interactions

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Memory CD4 T cells that express CXCR5 provide accelerated help to B cells

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Vaccination with DNA encoding internal proteins of influenza virus does not require CD8(+) cytotoxic T lymphocytes: either CD4(+) or CD8(+) T cells can promote survival and recovery after challenge

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Roles of CD4+ T-cell-independent and -dependent antibody responses in the control of influenza virus infection: evidence for noncognate CD4+ T-cell activities that enhance the therapeutic activity of antiviral antibodies

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

IL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4+ T cells for heterosubtypic protection

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Transcriptional control of rapid recall by memory CD4 T cells

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Memory CD4 T cell-mediated immunity against influenza A virus: more than a little helpful

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Memory CD4+ T-cell-mediated protection depends on secondary effectors that are distinct from and superior to primary effectors

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Effector T cell differentiation: are master regulators of effector T cells still the masters?

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Mucosal pre-exposure to Th17-inducing adjuvants exacerbates pathology after influenza infection

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Intranasal vaccination promotes detrimental Th17-mediated immunity against influenza infection.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

IL-21R signaling suppresses IL-17+ gamma delta T cell responses and production of IL-17 related cytokines in the lung at steady state and after Influenza A virus infection

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Type I interferon induction during influenza virus infection increases susceptibility to secondary Streptococcus pneumoniae infection by negative regulation of γδ T cells

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Neutrophil trails guide influenza-specific CD8⁺ T cells in the airways

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Intraepithelial T-cell cytotoxicity, induced bronchus-associated lymphoid tissue, and proliferation of pneumocytes in experimental mouse models of influenza

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Natural and long-lasting cellular immune responses against influenza in the M2e-immune host

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Vaccine-induced Th17 cells are established as resident memory cells in the lung and promote local IgA responses

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Structure of the extracellular domain of matrix protein 2 of influenza A virus in complex with a protective monoclonal antibody

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

An H5N1-based matrix protein 2 ectodomain tetrameric peptide vaccine provides cross-protection against lethal infection with H7N9 influenza virus.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Universal influenza vaccines: Shifting to better vaccines.

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers

1 reference

https://api.crossref.org/works/10.1038%2FMI.2017.14

7 January 2021

MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants

1 reference

12 December 2020

Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit.

1 reference

12 December 2020

Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein.

1 reference

12 December 2020

Crystal Structure of the Conserved Amino Terminus of the Extracellular Domain of Matrix Protein 2 of Influenza A Virus Gripped by an Antibody

1 reference

12 December 2020

Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity.

1 reference

12 December 2020

Vaccine-generated lung tissue-resident memory T cells provide heterosubtypic protection to influenza infection

1 reference

12 December 2020

Two better cell lines for making hybridomas expressing specific T cell receptors.

1 reference

12 December 2020

Memory CD4 T cells in influenza.

1 reference

12 December 2020

Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin.

1 reference

12 December 2020

Memory T follicular helper CD4 T cells

1 reference

12 December 2020

Mice can recover from pulmonary influenza virus infection in the absence of class I-restricted cytotoxic T cells

1 reference

12 December 2020

Identifiers

DOI

10.1038/MI.2017.14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28295019%20AND%20SRC:MED&resulttype=core&format=json

5 April 2020

1 reference